Clinical Trials Logo

Arthritis, Rheumatoid clinical trials

View clinical trials related to Arthritis, Rheumatoid.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT03546335 Suspended - Clinical trials for Rheumatoid Arthritis

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

This is a single center exploratory imaging study investigating the initial application of zirconium-89 Deferoxamine B Certolizumab pegol (89Zr-DFO-CZP) PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging.

NCT ID: NCT02686320 Suspended - Clinical trials for Rheumatoid Arthritis

Prospective Study of Patients With Rheumatoid Arthritis After the Age of 65

PRESAGE
Start date: March 29, 2016
Phase:
Study type: Observational

Rheumatoid arthritis (RA) is associated with a higher prevalence of infections, malignancies, osteoporotic fractures and cardiovascular diseases. Few data are available regarding the prevalence and severity of these comorbidities in elderly RA patients. The purpose of this study is to determine the effect of age on prevalence and severity of comorbidities in RA.

NCT ID: NCT02639988 Suspended - Type 2 Diabetes Clinical Trials

Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years

INSPIRED
Start date: April 13, 2016
Phase:
Study type: Observational

The purpose of this study is to determine whether patients with rheumatoid arthritis and type 2 diabetes experience a more severe disease course compared to control patients with osteoarthritis and type 2 diabetes

NCT ID: NCT00777816 Suspended - Clinical trials for Rheumatoid Arthritis

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Start date: February 2009
Phase: Phase 2
Study type: Interventional

Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA). It is hypothesized that administration of XOMA 052 is likely to improve inflammatory control in subjects with RA.